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Background. A range of plasma volume expanders is used clinically, often in settings where
haemostasis may already be impaired. The haemostatic agent, recombinant activated factor VII
(rFVIIa, NovoSeven
w), may be used to improve haemostasis but potential interactions with
different volume expanders are poorly understood.
Methods. Clot formation was measured by thromboelastography (TEG) using blood from
healthy volunteers. In vitro effects of rFVIIa with haemodilution, acidosis, and hypothermia were
examined. Conditions were induced by dilution with NaCl (0.9%), lactated Ringer’s solution,
albumin 5%, or hydroxyethyl starch (HES) solutions [MW (molecular weight) 130–670 kDa];
by adjusting pH to 6.8 with 1 M HEPES (N-2-hydroxyethylpiperazine-N0-2-ethanesulphonic
acid) buffer; or by reducing temperature to 328C. We also studied the effect of low vs high
MW HES (MW 200 vs 600 kDa) and rFVIIa on in vivo bleeding time (BT) in rabbits.
Results. Haemodilution progressively altered TEG parameters. rFVIIa improved TEG par-
ameters in the presence of acidosis, hypothermia or 20% haemodilution (P,0.05). At 40% hae-
modilution, the rFVIIa effect was diminished particularly with high MW HES. In vivo, rFVIIa
shortened the BT (P,0.05) with low but not high MW HES.
Conclusions. Efﬁcacy of rFVIIa was affected by the degree of haemodilution and type of
volume expander, but not by acidosis or hypothermia.
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Administration of intravascular ﬂuids to expand plasma
volume is a key component in the treatment of hypovolaemic
shock. Practices for selecting plasma volume expanders vary
across clinical situations and countries.
1 Important factors
include the volume expanding effect, risk of pulmonary
oedema, cost, and potential impact on haemostasis.
1 In surgi-
cal critical care, where confounding factors such as hypother-
mia and acidosis may be present, the potential impact of
volume expanders on haemostasis is particularly important.
2
Common plasma volume expanders include normal
saline (NS), lactated Ringer’s solution (LR), hydroxyethyl
starches (HES), albumin, and gelatins.
12Alterations in
coagulation function have been documented for each of
these, with both the level of haemodilution and the nature
of the colloid molecule playing a role. Crystalloids (NS
and LR) have been shown in vitro and in vivo to induce a
hypercoagulable state.
34While the effects on coagulation
for natural colloids such as albumin and gelatin appear
relatively minor, the impact of synthetic colloids such as
dextrans and hetastarches can be much more signiﬁcant.
2
For hetastarches, higher molecular weight (MW), molar
substitution, and C2:C6 ratios have been related to
impaired haemostatic parameters.
5–8
While maintenance of circulatory volume during surgical
procedures is important, haemostasis is the primary task.
Coagulopathy can result in continued blood loss from diffuse
capillary bleeding, even after surgical repair of vascular
structures. Under these conditions, haemostatic agents such
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rFVIIa acts at the site of injury to enhance thrombin gener-
ation, leading to a stable ﬁbrin plug.
9 This drug is established
for the treatment of bleeding episodes and for the prevention
of bleeding during surgery or invasive procedures in patients
with congenital haemophilia A and B with inhibitors to
coagulation factors VIII (FVIII) or IX (FIX) or an expected
high anamnestic response to FVIII or FIX. Additional indi-
cations include acquired haemophilia, congenital FVII
deﬁciency, and Glanzmann’s thrombasthenia refractory to
platelet transfusion.
10 Based on several case reports and ran-
domized clinical trials, the efﬁcacy of rFVIIa appears to
extend to a number of applications outside haemophilia,
including trauma
11 and others,
10 although these are not yet
approved by regulatory agencies.
There appears to be a population of critically ill trauma
patients who do not respond to rFVIIa because of factors
including haemodilution, acidosis, and hypothermia.
12 13
Some experimental studies have examined the effect of
rFVIIa in the presence of such factors as haemodilution,
acidosis, and hypothermia, either individually or in
selected combinations.
14–16 However, no studies have sys-
tematically addressed the potential impact of various
plasma volume expanders on the efﬁcacy of rFVIIa, or the
potential interactions of plasma volume expanders with
factors such as hypothermia or acidosis. In this paper, we
ﬁrst present in vitro experiments examining the effects of
volume expander type, degree of haemodilution, hypother-
mia, acidosis, and rFVIIa on blood clotting. We then
report results of an in vivo study that speciﬁcally addressed
our main in vitro ﬁnding, the differential effect of low and
high MW hetastarches on the apparent efﬁcacy of rFVIIa.
Methods
In vitro coagulation studies
Human WB collection
Blood was obtained by antecubital venepuncture using a
21-gauge needle from 42 healthy volunteers. Informed
consent was obtained in accordance with the local human
use review committee (Rigshospitalet, Copenhagen,
Denmark). Blood was collected into tubes containing
sodium citrate (0.13 M) at 1:9 v/v citrate to blood, and the
ﬁrst tube of blood was discarded. After 30 min at room temp-
erature, blood samples were used for in vitro experiments.
Haemodilution experiments
A series of seven in vitro haemodilution experiments were
performed. For each experiment a 3 4 factorial design
was used with each of the six subjects represented within
each factorial combination. Final concentrations of 25 or
200 nM rFVIIa were used to simulate in vivo doses of 90
or 720 mgk g
21, respectively.
Before use, volume expanders were mixed with 0.13 M
sodium citrate (10% v/v) to maintain anticoagulation of hae-
modiluted whole blood (WB). WB was diluted by 20, 40,
and 60% (v/v) with one of the following solutions: NaCl
(0.9%), LR (Fresnius Kabi, Uppsala, Sweden), human serum
albumin (HSA; 5% solution; Sigma-Aldrich, Steinheim,
Germany), and the HES Voluven
w (HES130; average MW
130 kDa/molar substitution ratio 0.4; Fresenius Kabi, Bad
Homburg, Germany), Haes-steril
w (HES200; 10% solution;
average MW 200 kDa/molar substitution ratio 0.5; Fresenius
Kabi, Bad Homburg, Germany, diluted to 6% with isotonic
NaCl before use); Hespan
w (HES600; 6% hetastarch; average
MW 600 kDa/molar substitution ratio 0.7; Braun Medical
Inc., Irvine, CA, USA); and Hextend
w (HES670; 6% hetas-
tarch; average MW 670 kDa/molar substitution ratio 0.75; in
Lactated Electrolyte Injection; BioTime Inc., Berkeley, CA,
USA). Colloids were in NaCl 0.9% unless otherwise noted.
Effects of acidosis and hypothermia
Blood was manipulated in vitro to induce the following
three conditions: (1) temperature 378C, pH 7.4; (2) temp-
erature 328C, pH 7.4; and (3) temperature 378C, pH 6.8.
Either 0 or 25 nM rFVIIa was added to each condition.
Acidosis was simulated by adjusting WB pH using 140 ml
of N-2-hydroxyethylpiperazine-N0-2-ethanesulphonic acid
(HEPES) 1 M buffer to 2 ml WB. Hypothermia was
simulated by lowering the temperature of WB to 328Co n
the thromboelastograph (TEG).
Combined acidosis, hypothermia, and haemodilution
Blood was haemodiluted 20% using LR, NaCl, albumin,
HES200, HES600, or HES670, and pH and temperature
were adjusted as mentioned above. Undiluted WB at pH
7.4 and 378C served as a control. Under each of these
conditions, either 0 or 25 nM rFVIIa was added.
TEG WB coagulation analysis
Coagulation was initiated by adding tissue factor 1:50 000
v/v (Innovin
w, Dade Behring, Deerﬁeld, IL, USA) to WB
and recalcifying with 15 mM calcium chloride. Blood,
tissue factor, and rFVIIa or buffer (HEPES 20 mM, 150
mM NaCl, and BSA 2%) were combined and inverted ﬁve
times before adding to a TEG cup containing CaCl2.
Clotting time (R), velocity of clot formation (alpha angle),
and maximum strength of the clot (maximum amplitude,
MA) were recorded using a 5000 series TEG analyser
(Haemoscope Corporation, Niles, IL, USA).
In vivo bleeding study
Animals
Twenty-four female New Zealand white rabbits (Charles
River, Germany) weighing 2.0–2.9 kg were housed in
colonies of 8–10 with free access to food and water. The
study was approved by the Danish Animal Experiments
Inspectorate. After 7 days acclimation, rabbits were
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21 (Stesolid,
Alpharma, Oslo, Norway) i.v. Thereafter, pentobarbital
sodium (5%) was administered (i.v.) to effect and sup-
plement as needed. Catheters were placed in the right
carotid artery and jugular vein, and left femoral artery.
The carotid catheter was connected to a pressure transdu-
cer (Gould P23 XL transducer and BD 9 recorder, Erik
Blichfeldt, Kolding, Denmark). Core temperature (rectal)
was maintained at 388C using a heating blanket.
Baseline bleeding measurements
Each anaesthetized rabbit was positioned on a specially
designed table, and a forepaw was placed in a beaker con-
taining 500 ml water (378C). After 10 min, bleeding was
initiated by cutting 2 mm of the nail of the third digit with a
spring-loaded sliding blade guillotine nail clipper, to induce
combined arterial and venous bleeding. The paw was placed
in water at 378C and bleeding time (BT) was recorded.
The total BT was deﬁned as the sum of the duration of all
the bleeding episodes (primary and re-bleeding) during the
15 min observation period. If baseline BT exceeded 10 min
the rabbit was excluded from the experiment and replaced.
Haemodilution and treatment with rFVIIa
After baseline BT measurements, rabbits were randomly
allocated to treatment according to Table 1.
After 10 min stabilization, 20% of the blood volume
(estimated as 7% of body weight) was withdrawn via the
femoral catheter .5 min. The withdrawn volume was
replaced with (378C) HES200 or HES600 infused through
the jugular vein over the next 5 min, followed by a resting
period of 5 min. This was repeated twice. Assuming full
mixing of blood and haemodiluent at each step, the ﬁnal
haemodilution was 20%þ20% 0.8þ20% 0.8 0.8¼
48.8% of total blood volume.
After the ﬁnal haemodilution step, cuticle bleeding was
induced on the paw opposite the baseline paw. After 5
min, animals received either 5 mg kg
21 rFVIIa or vehicle
(10 mM Glycyl-glycine buffer; 150 mM NaCl, 10 mM
CaCl2, pH 7.5) via the jugular catheter. BT was recorded.
Animals were killed after 60 min.
Statistical analysis
Each in vitro experiment was analysed by a three-way
mixed analysis of variance model with donor, rFVIIa
dose, and experimental condition as factors. The main
effects of the three factors and the interaction between
experimental condition and rFVIIa dose were considered
ﬁxed; the interactions between donor and the other two
factors were considered random. Comparisons were made
with normal baseline and with the 0 nM FVIIa dose level
within each experimental condition. Data are expressed as
a mean percentage of normal baseline and 95% conﬁdence
intervals. Means (with 5–95 percentiles) for the normal
baselines are also included as general reference points.
Data from the in vivo study were analysed by Kruskal–
Wallis test, followed by Dunns multiple comparison test.
Three animals (two from the HES600/rFVIIa group and
one from the HES600/vehicle group) died during the
experiment, and were excluded from analysis.
Results
In vitro studies
Effect of haemodilution
The R-value was signiﬁcantly reduced by all volume
expanders at the three tested dilutions compared with
normal undiluted WB except for HAES 130 at 20% hae-
modilution (Table 2). Addition of rFVIIa 25 or 200 nM
further reduced R within each ﬂuid and dilution level.
Alpha angle increased when blood was diluted up to 40%
with crystalloid or albumin solutions, and remained elevated
at 60% dilution with LR. When hetastarch solutions were
Table 2 Effect of in vitro haemodilution of WB on clotting time (R). Note:
plasma volume expanders (ﬂuid) are listed in descending order by MW from
lowest to highest. *Per cent change¼(R at target conditions/R at normal
baseline) 100; CI, conﬁdence interval.
†Statistically different from 0 dose of
rFVIIa without haemodilution (P,0.05).
‡Statistically different from 0 dose of
rFVIIa within haemodilution level (P,0.05)
Fluid rFVIIa dose Level of haemodilution [per cent
change
*(lower–upper CI)]
20% 40% 60%
NaCl 0 77 (69–86)
† 68 (61–76)
† 67 (60–74)
†
25 45 (40–50)
†‡ 43 (39–48)
†‡ 44 (40–49)
†‡
200 42 (38–47)
†‡ 38 (34–42)
†‡ 46 (41–52)
†‡
LR 0 80 (68–93)
† 66 (56–77)
† 60 (51–70)
†
25 42 (35–49)
†‡ 40 (34–48)
†‡ 43 (37–51)
†‡
200 38 (32–45)
†‡ 38 (32–45)
†‡ 41 (34–48)
†‡
Albumin 0 86 (81–92)
† 80 (75–85)
† 80 (75–85)
†
25 49 (45–53)
†‡ 47(43–51)
†‡ 53 (48–58)
†‡
200 43 (40–47)
†‡ 46 (42–50)
†‡ 54 (50–59)
†‡
HES130 0 123 (111–136)
† 94 (84–104)
† 85 (77–95)
†
25 54 (49–61)
†‡ 60 (54–67)
†‡ 63 (57–70)
†‡
200 54 (48–60)
†‡ 52 (47–58)
†‡ 61 (55–68)
†‡
HES200 0 89 (81–97)
† 70 (64–76)
† 71 (65–77)
†
25 45 (41–50)
†‡ 48 (44–54)
†‡ 53 (48–59)
†‡
200 44 (40–49)
†‡ 43 (39–48)
†‡ 50 (45–56)
†‡
HES600 0 89 (84–94)
† 90 (85–95)
† 92 (87–97)
†
25 51 (48–54)
†‡ 52 (49–55)
†‡ 58 (55–61)
†‡
200 45 (42–47)
†‡ 49 (46–52)
†‡ 58 (55–61)
†‡
HES670 0 94 (82–108) 79 (69–91)
† 78 (67–89)
†
25 56 (45–69)
†‡ 62 (50–76)
†‡ 70 (57–87)
†
200 53 (43–66)
†‡ 53 (43–66)
†‡ 61 (49–75)
†‡
Table 1 Random allocation of rabbits to treatment
Group Number Haemodilution Treatment
A 6 60% HES600 Vehicle
B 6 60% HES600 rFVIIa 2 5m gk g
21
C 6 60% HES200 Vehicle
D 6 60% HES200 rFVIIa 2 5m gk g
21
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326used, the alpha angle was unchanged or decreased at each
level of dilution (Table 3). At 20% haemodilution, rFVIIa 25
or 200 nM increased the alpha angle for all ﬂuids, with the
alpha angle approaching or exceeding 100% of baseline in
each case. At 40% haemodilution, the alpha angle after
addition of rFVIIa for albumin, LR, and NaCl followed
patterns similar to the respective patterns at the 20% haemo-
dilution. For HES130 and HES200, increases were observed
only after addition of 200 nM rFVIIa at 40% haemodilution.
Alpha angle was not increased by any dose of rFVIIa when
blood was haemodiluted 40% with either HES600 or
HES670. At 60% haemodilution the effect of rFVIIa on the
alpha angle was abolished.
At 20% haemodilution, MA decreased when albumin or
hetastarches were used, but not with LR or NaCl (Table 4).
At higher levels of haemodilution, MA decreased for all
ﬂuids, with numerically greater decrements for hetastarches.
The MA was increased by both rFVIIa concentrations at 20
and 40% haemodilution with albumin and by rFVIIa 200
nM with LR, NaCl, HES130, and HES670. At 60% haemo-
dilution, rFVIIa did not affect MA.
Pooled (n¼42 subjects) baseline TEG parameters (mean
and 5–95 percentiles) were 562 s (340–730) for R, 52.08
(37.6–63.0) for alpha angle, and 61.1 mm (49.6–69.4)
for MA.
Effects of hypothermia and acidosis
Clotting time (R) was not affected by acidosis, whereas
alpha angle and MA were signiﬁcantly decreased in acidic
blood (Table 5). Addition of rFVIIa decreased the R-time,
and increased the alpha angle and MA. There was no stat-
istical interaction (P.0.20) between acidosis and rFVIIa,
indicating that the effect of rFVIIa on these TEG par-
ameters was similar at normal or acidic conditions.
Hypothermia did not statistically alter any TEG par-
ameter (Table 5). Addition of rFVIIa 25 nM signiﬁcantly
decreased R-time and increased alpha angle and MA.
There was no statistical interaction (P.0.20) between
temperature and rFVIIa, indicating that the effects of
rFVIIa on these TEG parameters was similar at normal
and hypothermic conditions.
Effects of combined acidosis, hypothermia,
and haemodilution
The R-value was signiﬁcantly prolonged for all ﬂuids
under combined acidic and hypothermic conditions, while
the alpha angle and MA were either numerically or statisti-
cally reduced (Table 6). Addition of rFVIIa signiﬁcantly
shortened R compared with baseline with each volume
expander. Alpha angle was increased from baseline by the
addition of rFVIIa with NaCl, LR, albumin, and HES670,
Table 4 Effect of in vitro haemodilution of WB on clot MA. Note: plasma
volume expanders (ﬂuid) are listed in descending order by MW from lowest
to highest. *Per cent change¼(MA at target conditions/MA at normal
baseline) 100; CI, conﬁdence interval.
†Statistically different from 0 dose of
rFVIIa without haemodilution (P,0.05).
‡Statistically different from 0 dose of
rFVIIa within haemodilution level (P,0.05)
Fluid rFVIIa
dose
Level of haemodilution [per cent change
*(lower–
upper CI)]
20% 40% 60%
NaCl 0 100 (94–107) 89 (83–95)
† 74 (69–80)
†
25 100 (94–107) 92 (86–98)
† 75 (70–81)
†
200 104 (97–111) 95 (89–102)
‡ 70 (65–75)
†
LR 0 97 (93–101) 90 (87–94)
† 77 (74–80)
†
25 100 (96–105) 93 (89–97)
† 74 (71–77)
†
200 103 (98–107)
‡ 95 (91–99)
†‡ 77 (74–80)
†
Albumin 0 93 (88–97)
† 88 (83–92)
† 70 (67–74)
†
25 105 (100–111)
†‡ 94 (90–99)
†‡ 69 (66–73)
†
200 104 (99–109)
‡ 92 (88–97)
†‡ 68 (65–72)
†
HES130 0 80 (74–86)
† 61 (57–66)
† 51 (47–55)
†
25 83 (77–90)
† 63 (58–68)
† 45 (42–49)
†‡
200 84 (78–91)
† 67 (62–73)
†‡ 48 (44–52)
†
HES200 0 88 (80–96)
† 70 (64–77)
† 56 (51–61)
†
25 86 (79–94)
† 68 (62–74)
† 49 (45–54)
†‡
200 88 (81–97)
† 74 (67–80)
† 49 (45–54)
†‡
HES600 0 82 (76–88)
† 72 (67–77)
† 54 (50–58)
†
25 87 (80–94)
† 72 (67–78)
† 55 (51–60)
†
200 87 (80–94)
† 70 (65–76)
† 54 (50–59)
†
HES670 0 77 (72–81)
† 67 (71–53)
† 53 (50–56)
†
25 81 (75–86)
† 65 (60–69)
† 48 (44–51)
†‡
200 83 (78–89)
†‡ 69 (64–73)
† 51 (48–55)
†
Table 3 Effect of in vitro haemodilution of WB on the velocity of clot
formation (alpha angle). Note: plasma volume expanders (ﬂuid) are listed in
descending order by MW from lowest to highest. *Per cent change¼(angle at
target conditions/angle at normal baseline) 100; CI, conﬁdence interval.
†Statistically different from 0 dose of rFVIIa without haemodilution (P,0.05).
‡Statistically different from 0 dose of rFVIIa within haemodilution level
(P,0.05)
Fluid rFVIIa
Dose
Level of haemodilution [per cent change
*(lower–
upper CI)]
20% 40% 60%
NaCl 0 116 (108–125)
† 118 (110–127)
† 107 (99–115)
25 126 (117–136)
† 122 (114–132)
† 103 (96–111)
200 130 (121–140)
†‡ 130 (121–140)
† 105 (97–113)
LR 0 112 (102–124)
† 126 (113–139)
† 123 (111–136)
†
25 130 (117–145)
†‡ 129 (116–144)
† 106 (95–118)
‡
200 142 (127–158)
†‡ 140 (125–156)
†‡ 120 (108–134)
†
Albumin 0 111 (104–118)
† 112 (105–119)
† 101 (95–107)
25 134 (124–146)
†‡ 130 (119–140)
†‡ 100 (92–109)
200 136 (126–148)
†‡ 126 (116–137)
†‡ 99 (91–107)
HES130 0 68 (60–76)
† 74 (66–83)
† 62 (55–70)
†
25 94 (84–106)
‡ 73 (65–82)
† 60 (53–67)
†
200 107 (95–120)
‡ 92 (82–104)
‡ 60 (54–68)
†
HES200 0 94 (84–105) 92 (82–102) 73 (65–82)
†
25 108 (97–121)
‡ 88 (78–99)
† 62 (56–69)
†‡
200 115 (103–129)
†‡ 102 (92–114)
‡ 65 (58–72)
†‡
HES600 0 94 (85–104) 85 (77–94)
† 65 (59–71)
†
25 106 (96–118)
‡ 90 (81–99)
† 65 (58–72)
†
200 107 (96–119)
‡ 84 (75–93)
† 63 (57–70)
†
HES670 0 82 (72–93)
† 88 (77–100)
† 61 (53–69)
†
25 100 (87–116)
‡ 84 (73–98)
† 53 (46–61)
†
200 106 (92–122)
‡ 88 (76–101) 63 (54–72)
†
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observed with HES600 or HES130. MA was improved by
the addition of rFVIIa with NaCl and albumin but not
with HES600, HES 130, or HES670.
In vivo study
Haemodilution with HES200 or HES600 signiﬁcantly pro-
longed primary BT, as 10 out of 11 animals bled continu-
ously for 1 h. The primary BT was signiﬁcantly reduced
after treatment with rFVIIa in animals haemodiluted with
HES200 but not HES600 (Fig. 1). Similar patterns were
observed for total BT.
Discussion
Data presented here conﬁrm previous ﬁndings that
although all plasma volume expanders tested shortened
initial coagulation time, clot functional characteristics
varied greatly. As expected, increased haemodilution pro-
gressively compromised clot mechanical characteristics,
reﬂecting at least in part, an impact of reduced ﬁbrinogen
and platelet concentrations. However, at a given level of
haemodilution, hetastarches, particularly high MW heta-
starches, produced the greatest impairment compared with
albumin and crystalloid solutions. Additionally, blood
diluted with hetastarch solutions appeared less responsive
to rFVIIa, especially with high MW hetastarches.
To enable us to examine a range of volume expanders
and conditions, we focused on a single method, TEG, to
assess blood clotting in vitro. Additionally, we performed
an in vivo experiment to further investigate a single
key ﬁnding. We did not speciﬁcally address thrombin
generation, ﬁbrin assembly, or platelet function. These
limitations must temper our interpretation. Because experi-
mental modiﬁcation of normal blood or animals cannot
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Fig 1 Primary bleeding time (BT) in rabbits haemodiluted with 60%
HES600 (MW¼600 000) or HES200 (MW¼200 000) treated with
vehicle or with 5 mg kg
21 rFVIIa 5 min after induction of bleeding.
Observation period was 3600 s. Baseline represents BT in the same
rabbits from the contralateral paw before haemodilution with an
observation period of 900 s. Lines within the graph represent medians.
Table 6 Effect of in vitro addition of rFVIIa with combined acidosis, hypothermia, and 20% haemodilution on TEG parameters in WB from healthy volunteers.
Note: plasma volume expanders (ﬂuid) are listed in descending order by MW from lowest to highest; all ﬁnal dilutions 20%. *Per cent change¼(parameter at
target conditions/parameter at normal baseline) 100; CI, conﬁdence interval.
†Statistically different from normal baseline (P,0.05).
‡Statistically different from
normal baseline (P,0.01).
}Statistically different from 0 dose of rFVIIa within ﬂuid (P,0.05).
§Statistically different from 0 dose of rFVIIa within ﬂuid
(P,0.01)
Haemodilution agents Clotting time (R) [per cent change*
(mean and CI, n56)]
Alpha angle [per cent change*
(mean and CI, n56)]
Maximum amplitude [per cent
change* (mean and CI, n56)]
rFVIIa, 0 nM FVIIa, 25 nM rFVIIa, 0 nM FVIIa, 25 nM rFVIIa, 0 nM FVIIa, 25 nM
NaCl 119 (109–130)
‡ 77 (70–84)
‡§ 82 (71–94)
‡ 101 (88–116)
§ 80 (75–85)
‡ 87 (82–93)
‡§
LR 122 (111–133)
‡ 74 (68–82)
‡§ 94 (81–108) 107 (93–123) 88 (82–93)
‡ 91 (86–97)
‡
Albumin 126 (115–138)
‡ 77 (70–84)
‡§ 64 (56–74)
‡ 90 (79–104)
§ 67 (63–71)
‡ 80 (75–85)
‡§
HES130 136 (125–149)
‡ 90 (82–99)
†§ 68 (59–78)
‡ 68 (59–78)
‡ 66 (62–70)
‡ 64 (60–68)
‡
HES600 133 (122–146)
‡ 85 (78–93)
‡§ 61 (53–70)
‡ 67 (58–77)
‡ 67 (63–71)
‡ 63 (59–67)
‡}
HES670 129 (117–141)
‡ 80 (74–88)
‡§ 67 (59–77)
‡ 84 (73–97)
†§ 71 (67–76)
‡ 73 (68–78)
‡
Table 5 Effect of in vitro addition of rFVIIa on TEG parameters in WB from healthy volunteers under acidosis and hypothermia. Data shown as per cent
change from baseline. *Signiﬁcantly different compared with normal WB for R, alpha angle, and MA (P,0.01).
†Signiﬁcantly different compared with normal
WB for R, alpha angle, and MA (P,0.05).
‡Signiﬁcantly different compared with 0 nM rFVIIa for R, alpha angle, and MA (P,0.05)
Clotting time (R) (mean and CI,
n56)
Alpha angle (mean and CI, n56) Maximum amplitude (MA) (mean
and CI, n56)
rFVIIa, 0 nM rFVIIa, 25 nM rFVIIa, 0 nM rFVIIa, 25 nM rFVIIa, 0 nM rFVIIa, 25 nM
Normal whole blood (WB) (n¼6) 100 65 (58–72)
*‡ 100 109 (98–123) 100 105 (102–108)
*‡
Acidosis (pH 6.8) 107 (84–136) 69 (54–88)
*‡ 82 (72–93)* 109 (96–125)
‡ 96 (93–99)
† 105 (101–109)
*‡
Hypothermia (328C) 119 (92–153) 66 (51–85)
*‡ 94 (82–109) 111 (98–128)
‡ 98 (94–101) 104 (100–108)
†‡
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328fully reﬂect the pathophysiological mechanisms present in
patients, caution should be exercised in extrapolating the
present ﬁndings to the patient setting. These limitations
notwithstanding, we believe that we can draw some con-
clusions regarding potential mechanisms.
Hetastarches exert a number of effects on the haemo-
static systems that are distinct from a simple dilutional
effect, including reductions in FVIII and vWF levels,
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impaired ﬁbrin polymerization and cross-linking,
18–20 and
reduced platelet function.
5 These have been related both to
MW and to the molar substitution ratio of the hetastarch,
with effects generally more pronounced with higher MW
and higher molar substitution ratios.
5–8As the lower MW
hetastarches used in the present study also had the lowest
molar substitutions [HES 130 (130/0.4), HES 200 (200/
0.5), HES600 (600/0.7), and HES670 (670/0.75)], it is not
possible to differentiate between the potential effects of
MW or molar substitution ratio.
In a recent study that examined plasma clotting kinetics
after infusion of 20 ml kg
21 high MW hetastarch solution
in rabbits (28% estimated blood volume), alpha angle and
shear elastic modulus (a measure of clot strength) were
reduced by 29 and 73%, respectively.
20 These parameters
were partially restored by in vitro addition of either factor
XIII or ﬁbrinogen. Addition of thrombin shortened the R
time but had no effect on clot development or strength. It
was concluded that hetastarch decreased clot propagation
and strength primarily because of decreased FXIIIa-ﬁbrin
polymer cross-linking. These results suggest that the
decrement in clot development and strength cannot be
overcome by the actions of thrombin alone, although rate
of clot initiation can be enhanced. Recombinant FVIIa
functions by enhancing thrombin production at the site of
injury.
9 The fact that R was shortened by rFVIIa at all
levels of haemodilution in the present study suggests that
thrombin production was enhanced by the addition of
rFVIIa. Therefore, it does not appear that hetastarch
impaired the ability of rFVIIa to enhance thrombin gener-
ation. Hetastarch-induced ﬁbrin structural defects may be
resistant to correction by thrombin, which may explain
why rFVIIa did not consistently improve alpha angle or
MA when hetastarch was used in the present study.
Reducing the pH from 7.4 to 7.0 reduces rFVIIa enzy-
matic activity 60–90%.
16 Therefore, the reduced clinical
efﬁcacy of rFVIIa observed in acidosis,
12 21–23 may be
related to lower enzymatic rates. However, it is not clear at
what point reduced enzymatic rate might impact clinical
efﬁcacy because rFVIIa administration increases circulat-
ing FVIIa levels approximately 100-fold. Our ﬁndings
suggest that rFVIIa may offset pH-related changes in enzy-
matic rates. This may, in part, explain clinical reports
documenting some individual patients who did and others
who did not respond to rFVIIa at a pH ,7.2.
12 21 22
Further studies are required to determine the relative roles
of blood pH and other acidosis-related factors in deter-
mining the efﬁcacy of rFVIIa in acidotic patients.
Our inability to detect a statistical impairment of TEG
parameters under hypothermic conditions contrasts with
previous ﬁndings.
24 25 Hypothermia reduces coagulation
enzymatic rates
16 and platetet enzymatic and secretory
rates.
26 In a recent report, rFVIIa improved TEG par-
ameters at temperatures of 28–318C.
25 Our data provide
further evidence for this effect. The ability of rFVIIa to
enhance haemostatic parameters in hypothermia is consist-
ent with its retention of enzymatic activity between 37 and
328C in vitro
16 and with clinical reports of efﬁcacy in
hypothermic patients.
13 21
When the conditions of hypothermia, acidosis, and 20%
haemodilution were combined, R was consistently pro-
longed above normal baseline. This was similar to the
pattern observed for undiluted hypothermic blood, but
quite different from the effects of haemodilution alone.
Alpha angle and MA were reduced below the baseline, a
pattern that was also more similar to the responses to
hypothermia and acidosis alone than to the responses to
20% haemodilution. These ﬁndings suggest that hypo-
thermia and acidosis had the greater impact on TEG
parameters than did the type of ﬂuid.
A different pattern was noted when examining the
responsiveness to 25 nM rFVIIa. The R was shortened by
addition of rFVIIa, regardless of the plasma volume expan-
der used, consistent with the results for acidosis, hypo-
thermia, or haemodilution alone. However, the responses
for the alpha angle and MA under combined conditions
diverged from the rFVIIa responses for acidosis or
hypothermia alone, and more closely followed the patterns
observed in the isolated haemodilution experiments. When
NaCl or albumin was used in the presence of combined
acidosis and hypothermia, the alpha angle was normalized
by rFVIIa. However, when hetastarches were used in the
presence of acidosis and hypothermia, the alpha angle was
improved in only one case (HES670) and the post-rFVIIa
values remained below the normal baseline for all heta-
starches. These data suggest that the response to rFVIIa
was more dependent on the type of plasma expander used
than on the effects of hypothermia and acidosis.
The potential differential effect of low vs high MW
hetastarch on the activity of rFVIIa was further addressed
in vivo. The consistent extension of BT after haemodilution
with hetastarch solutions in normal rabbits in the present
study is consistent with results reported for patients under-
going acute normovolemic haemodilution in preparation for
surgery.
27 Administration of rFVIIa reduced BT in rabbits
that were haemodiluted with low MW hetastarch (HES200)
but not in rabbits administered with high MW hetastarch
(HES600). In vitro, we observed that the alpha angle was
improved in response to rFVIIa at 40% haemodilution
with lower MW hetastarches, HES130, and HES200, but
not with higher MW hetastarches, HES600 or HES670.
Martinowitz et al.
15 reported improved haemostasis in
response to rFVIIa after severe liver injury in pigs that were
made coagulopathic by induction of hypothermia and
Effect of haemodilution on the activity of rFVIIa
329haemodilution with a 200 000 MW hetastarch. However, in
a study using a similar animal model, but with a 600 000
MW hetastarch, rFVIIa did not alter blood loss.
14
Infusion of high MW hetastarch yields reductions in
vWF and FVIII:c well beyond those expected by simple
haemodilution.
681 7Considering the well-established efﬁ-
cacy of rFVIIa in haemophilia, it does not seem likely that
rFVIIa efﬁcacy would be limited by a hetastarch effect on
FVIII:c levels. As mentioned earlier, ﬁbrin polymerization
is negatively impacted by hetastarches,
18–20 and this could
have affected the efﬁcacy of rFVIIa. High MW has also
been related to a greater impairment of platelet function.
5
It appears that hetastarch molecules coat platelets non-
speciﬁcally, altering the interaction of GPIIb/IIIa receptors
with ﬁbrinogen. The present in vitro ﬁnding that the alpha
angle, a parameter related to platelet function, was more
responsive to rFVIIa when low MW than high MW heta-
starches were used, is consistent with such a platelet
effect. BT procedures are believed to be more dependent
on primary haemostasis than secondary haemostasis,
suggesting that the effects observed in the present, in vivo
study might have been related to platelet function.
Conclusion
We found progressive alterations in TEG parameters with
increasing haemodilution and observed greater impairments
with hetastarches than albumin or crystalloids. At 20% hae-
modilution, rFVIIa improved TEG parameters for all
volume expanders. However, blood diluted with hetastarch
solutions, particularly high MW hetastarches, appeared less
responsive to rFVIIa when the in vitro dilution reached
40%. In vivo, rFVIIa improved haemostasis in rabbits after
haemodilution with low MW but not high MW hetastarch.
It does not appear that hetastarch prevented rFVIIa
enhancement of thrombin generation, but instead that heta-
starch may have induced changes in ﬁbrin structure and
platelet function that were resistant to correction by throm-
bin, and, therefore, resistant to rFVIIa at high levels of
haemodilution. Recombinant FVIIa improved in vitro clot
formation under conditions of acidosis and hyperthomia.
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